Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

References

• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol. 2018;37(7):1739–1741. doi:10.1007/s10067-018-4090-6
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119. doi:10.1111/jdv.14868
   PubMed Web of Science ®Google Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26. doi:10.1038/jid.2012.194
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2021. doi:10.1007/s00403-021-02200-7
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673. doi:10.1111/dth.14673
   PubMed Web of Science ®Google Scholar
• Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis. Drugs. 2021;81(15):1751–1762. doi:10.1007/s40265-021-01612-z
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286.e10. doi:10.1016/j.jaad.2018.03.037
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532. doi:10.1136/annrheumdis-2017-212127
   PubMed Web of Science ®Google Scholar
• Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine. 2013;62(2):175–182. doi:10.1016/j.cyto.2013.03.014
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi:10.3389/fimmu.2020.01894
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152. doi:10.1056/NEJMoa2102383
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther Adv Chronic Dis. 2021;12:20406223211037846. doi:10.1177/20406223211037846
   Web of Science ®Google Scholar
• Ali Z, Matthews R, Al-Janabi A, Warren RB. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2021;17(10):1073–1081. doi:10.1080/1744666X.2021.1967748
   PubMed Web of Science ®Google Scholar
• Bimekizumab - prescribing information. Available from: https://www.ema.europa.eu/en/documents/assessment-report/bimzelx-epar-public-assessment-report_en.pdf. Accessed April 11, 2022.
   Google Scholar
• Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652–663. doi:10.1111/bjd.20827
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020;83(5):1367–1374. doi:10.1016/j.jaad.2020.05.105
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. [published correction appears in Lancet. 2021 Mar 27;397(10280):1182]. Lancet. 2021;397(10273):475–486. doi:10.1016/S0140-6736(21)00126-4
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE BRIGHT). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03598790?term=BE+BRIGHT&draw=2&rank=1. Accessed April 13, 2022.
   Google Scholar
• Griffith SK, Ahn GS, Wu JJ. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(12):1149–1150. doi:10.1056/NEJMc2113092
   PubMed Web of Science ®Google Scholar
• Oliveira DG, Faria R, Torres T. An overview of bimekizumab for the treatment of psoriatic arthritis: the evidence so far. Drug Des Devel Ther. 2021;15:1045–1053. doi:10.2147/DDDT.S267405
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;85(4):1028–1030. doi:10.1016/j.jaad.2021.01.025
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–567. doi:10.1111/ced.14979
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2):e13238. doi:10.1111/dth.13238
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;2022:1–5.
   Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. Safety of dupilumab in atopic patients during COVID-19 outbreak. J Dermatolog Treat. 2022;33(1):600–601. doi:10.1080/09546634.2020.1771257
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Gallo L, Caiazzo G, Ruggiero A, Fabbrocini G. Reply to “Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al. J Eur Acad Dermatol Venereol. 2022;36(1):e11–e13. doi:10.1111/jdv.17665
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. J Dermatolog Treat. 2022;33(1):592. doi:10.1080/09546634.2020.1769828
   PubMed Web of Science ®Google Scholar